What we're reading, December 28, 2016: a county in West Virginia is suing 3 national drug distributors for allegedly fueling the opioid epidemic; CDC awards new funding as another Zika case is reported in Texas; and first drug to treat spinal muscular atrophy approved.
A county in West Virginia, which has been hard hit by the opioid epidemic, is suing 3 of the nation’s largest prescription drug distributors. According to the Charleston Gazette-Mail, the lawsuit alleges that Cardinal Health, McKesson Corp, and AmerisourceBergen shipped an excessive number of opioids to the county and fueled the painkiller epidemic there. Meanwhile, Cardinal has settled with the state of New York over a similar case. The lawsuit claims the company failed to alert the Drug Enforcement Administration about suspiciously large orders of addictive painkillers in New York.
With new cases of the Zika virus reported in Texas, the CDC is sending $184 million to states and territories to continue the fight against the virus. Florida, Hawaii, and Texas are the states that will receive the largest amounts, and Puerto Rico is receiving $5 million, reported The Washington Post. The new funding announcement comes on the heels of a sixth locally-borne case of Zika in Cameron County, Texas.
The first drug to treat spinal muscular atrophy was approved on Friday. Biogen’s drug will treat a disease that affects 1 in 10,000 live births and is the leading genetic cause of death among infants, according to Reuters. The drug is approved across the full range and severity of the disease and is projected to have annual sales reaching $2 billion. Clinical trials of nusinersen dramatically improved motor milestones and extended survival.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More